Defective endothelially mediated pulmonary vasodilation in systemic sclerosis

Chest

Volumn 114, Issue 1, 1998, Pages 178-184

  Cailes, Jeremy ^a   Winter, Stephen ^b   Du Bois, Roland M ^a   Evans, Timothy W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NORWALK HOSPITAL   (United States)

Author keywords

Pulmonary vasodilation; Systemic sclerosis

Indexed keywords

ADENOSINE DERIVATIVE; NITRIC OXIDE; SUBSTANCE P;

ADULT; ARTICLE; CAPILLARY FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ENDOTHELIUM LESION; FEMALE; HEART OUTPUT; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LUNG ENDOTHELIUM; LUNG VASCULAR RESISTANCE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; VASODILATATION;

EID: 0031819178     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.1.178     Document Type: Article

References (32)

1. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75:65-74
2. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975; 4:351-68
3. Kahaleh MB, Sherer GK, LeRoy EC. Endothelial injury in scleroderma. J Exp Med 1979; 149:1326-35
4. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992; 5:757-62
5. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29:515-24
6. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82:139-48
7. Young RH, Mark GJ. Pulmonary vascular changes in scleroderma. Am J Med 1978; 64:998-1004
8. Liu SF, McCormack DG, Evans TW, et al. Evidence for two P2-purinoceptor subtypes in human small pulmonary arteries. Br J Pharmacol 1989; 98:1014-20
9. Morgan JM, McCormack DG, Griffiths MJD, et al. Adenosine as a vasodilator in primary pulmonary hypertension. Circulation 1991; 84:1145-49
10. Inbar S, Schrader BJ, Kaufmann E, et al. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension. J Am Coll Cardiol 1993; 21:413-18
11. Utterback DB, Staples ED, White SE, et al. Basis for the selective reduction of pulmonary vascular resistance in humans during infusion of adenosine. J Appl Physiol 1994; 76:724-30
12. Luu TN, Chester AH, O'Neil GS, et al. Effects of vasoactive neuropeptides on human saphenous vein. Br Heart J 1992; 67:474-77
13. Rees DD, Palmer RM, Hodson HF, et al. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 1989; 96:418-24
14. Archer SL, Kulik TJ, Chesler E, et al. The effects of substance P on the preconstricted pulmonary vasculature of the anesthetized dog. Proc Soc Exp Biol Med 1986; 183:19-27
15. Durkin RJ, Evans TW, Winter SM. Noninvasive estimation of pulmonary vascular resistance by stroke index measurement with an inert gas rebreathing technique. Chest 1994; 106:59-66
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90
17. Sackner M. Diffusing capacity, membrane diffusing capacity, capillary blood volume, pulmonary tissue volume, and cardiac output measured by a rebreathing technique. Am Rev Respir Dis 1975; 111:157-65
18. Bush A. Rebreathing method for the simultaneous measurement of oxygen consumption and effective pulmonary blood flow during exercise. Thorax 1988; 43:268-75
19. Evans TW, Dixon CM, Clarke B, et al. Comparison of neurokinin A and substance P on cardiovascular and airway function in man. Br J Clin Pharmacol 1988; 25:273-75
20. Vanhoutte PM, Rubanyi GM, Miller VM, et al. Modulation of vascular smooth muscle contraction by the endothelium. Annu Rev Physiol 1986; 48:307-20
21. Persson MG, Heqvist P, Gustafsson LE. Nerve-induced tachykinin-mediated vasodilation in skeletal muscle is dependent on nitric oxide formation. Eur J Pharmacol 1991; 205:295-301
22. Alpert MA, Pressly TA, Mukerji V, et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1981; 68:1687-91
23. Morgan JM, Griffiths MJD, du Bois R, et al. Hypoxic pulmonary vasoconstriction in systemic sclerosis and primary pulmonary hypertension. Chest 1991; 99:551-56
24. Baudouin SV, Bath P, Martin JF, et al. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993; 36:45-49
25. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-21
26. Uren NG, Ludman PF, Crake T, et al. Response of the pulmonary circulation to acetylcholine, calcitonin gene-related peptide, substance P and oral nicardipine in patients with primary pulmonary hypertension. J Am Coll Cardiol 1992; 19:835-41
27. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324:1539-47
28. Russ RD, Walker BR. Maintained endothelium-dependent pulmonary vasodilation following chronic hypoxia in the rat. J Appl Physiol 1993; 74:339-44
29. Bush A, Busst CM, Clarke B, et al. Effect of infused adenosine on cardiac output and systemic resistance in normal subjects. Br J Clin Pharmacol 1989; 27:165-71
30. Youssef P, Englert H, Bertouch J. Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 1993; 52:464-66
31. Harrison NK, McAnulty RJ, Haslam PL, et al. Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis. Thorax 1990; 45:606-10
32. Drenk F, Deicher HR. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. J Rheumatol 1988; 15:468-74